904 / 1631
PD1/PD-L1 in DLBCL
•
Investigation of nivolumab (anti PD-1), pembrolizumab (anti PD-1), avelumab (PD-
1), durvalumab (anti PD-L1) and atezoluimumab (PD-L1) in DLBCL
•
PD-L1 expressed on about 10-30% of patients with DLBCL (more frequent in
PMBL)
•
High is EBV +ve DLBCL and TCRLCL (Chen et al. Clin Canc Res 2013)
•
Nivoulumab ORR DLBCL 36% (n=11) median duration of response 22 weeks
(Lesokhin et al. ASH 2014)
•
Waiting for combination data…
(Chen et al. Clin Canc Res 2013)